Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients

Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients

(2012) Uyen Duong et al.   AMERICAN JOURNAL OF NEPHROLOGY

Erythropoietin: The swinging pendulum

(2012) Howard S. Oster et al.   LEUKEMIA RESEARCH

Erythropoiesis-Stimulating Agent Responsiveness and Mortality in Hemodialysis Patients: Results from a Cohort Study From the Dialysis Registry in Japan

(2011) Shingo Fukuma et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Association of Mean Weekly Epoetin Alfa Dose with Mortality Risk in a Retrospective Cohort Study of Medicare Hemodialysis Patients

(2011) Eric D. Weinhandl et al.   AMERICAN JOURNAL OF NEPHROLOGY

Addition of Darbepoetin Alfa to Dose-Dense Chemotherapy: Results From a Randomized Phase II Trial in Small-Cell Lung Cancer Patients Receiving Carboplatin Plus Etoposide

(2011) Sylke Nagel et al.   Clinical Lung Cancer

Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study

(2011) V. Panichi et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Chapter 9: Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2009: National and Centre-Specific Analyses

(2011) Julie Gilg et al.   NEPHRON CLINICAL PRACTICE

Iron, Inflammation, Dialysis Adequacy, Nutritional Status, and Hyperparathyroidism Modify Erythropoietic Response

(2010) A. E. Gaweda et al.   Clinical Journal of the American Society of Nephrology

What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?

(2010) Ajay K Singh   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

International trends in erythropoietin use and hemoglobin levels in hemodialysis patients

(2010) Philip A. McFarlane et al.   KIDNEY INTERNATIONAL

Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients

(2010) Alexander Kainz et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

(2010) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

(2009) Kamyar Kalantar-Zadeh et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Estimated Effect of Epoetin Dosage on Survival among Elderly Hemodialysis Patients in the United States

(2009) Y. Zhang et al.   Clinical Journal of the American Society of Nephrology

Relationship between Epoetin Alfa Dose and Mortality: Findings from a Marginal Structural Model

(2009) O. Wang et al.   Clinical Journal of the American Society of Nephrology

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL

(2009) Brian D. Bradbury et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients

(2008) R. D. Kilpatrick et al.   Clinical Journal of the American Society of Nephrology

Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality

(2008) Juan M. López-Gómez et al.   KIDNEY INTERNATIONAL

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

(2008) Lynda A. Szczech et al.   KIDNEY INTERNATIONAL

Hemoglobin Control, ESA Resistance, and Regular Low-Dose IV Iron Therapy: A Review of the Evidence

(2008) Ajay Singh   SEMINARS IN DIALYSIS